{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:07:20Z","timestamp":1781078840973,"version":"3.54.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To evaluate the efficacy of sodium butyrate (NaB) in ameliorating nonalcoholic fatty liver disease (NAFLD) in animals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Chinese and English databases (including PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wangfang Data, CQVIP, and SinoMed) were searched for literature related to NaB to improve the animal model of NAFLD from the establishment of each database to 2023-02. 2 researchers independently screened the literature and extracted the data. The SYRCLE tool was used to assess risk of bias. The extracted data were analyzed using Revman 5.3 and Stata 17.0.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 1008 relevant references were reviewed, and 12 animal experiments involving 192 animals were included in the analysis: 96 in the NaB group and 96 in the model group. The results showed that animals in the NaB group had significantly lower levels of alanine aminotransferase (standardized mean difference (<jats:italic toggle=\"yes\">SMD<\/jats:italic>)\u2005=\u2005\u22121.29, 95% confidence interval (<jats:italic toggle=\"yes\">CI<\/jats:italic>) (\u22122.08, \u22120.49), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.002], aspartate aminotransferase [<jats:italic toggle=\"yes\">SMD<\/jats:italic>\u2005=\u2005\u22121.13, 95% <jats:italic toggle=\"yes\">CI<\/jats:italic> (\u22121.75, \u22120.50), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.0004], NAFLD activity scores [<jats:italic toggle=\"yes\">SMD<\/jats:italic>\u2005=\u2005\u22123.19, 95%<jats:italic toggle=\"yes\">CI<\/jats:italic>(\u22124.80, \u22121.58), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.0001], triglyceride [<jats:italic toggle=\"yes\">SMD<\/jats:italic>\u2005=\u2005\u22121.28, 95%<jats:italic toggle=\"yes\">CI<\/jats:italic>(\u22121.66, \u22120.90), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001] and total cholesterol levels [<jats:italic toggle=\"yes\">SMD<\/jats:italic>\u2005=\u2005\u22121.39, 95%<jats:italic toggle=\"yes\">CI<\/jats:italic>(\u22122.11, \u22120.67), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.0002], interleukin-1\u03b2 [<jats:italic toggle=\"yes\">SMD<\/jats:italic>\u2005=\u2005\u22121.40, 95%<jats:italic toggle=\"yes\">CI<\/jats:italic> (\u22121.87, \u22120.92), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001], interleukin-6 [<jats:italic toggle=\"yes\">SMD<\/jats:italic>\u2005=\u2005\u22121.38, 95%<jats:italic toggle=\"yes\">CI<\/jats:italic> (\u22121.87, \u22120.90), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001], tumor necrosis factor-alpha [<jats:italic toggle=\"yes\">SMD<\/jats:italic>\u2005=\u2005\u22121.69, 95% <jats:italic toggle=\"yes\">CI<\/jats:italic> (\u22122.10, \u22121.28), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001], and other pro-inflammatory factors, and significantly higher tight junction protein-1 expression [<jats:italic toggle=\"yes\">SMD<\/jats:italic>\u2005=\u20051.06, 95% <jats:italic toggle=\"yes\">CI<\/jats:italic> (0.43,1.69), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.0009].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>NaB treatment improves liver function in animals with NAFLD, protected the liver tissue, reduced triglyceride and total cholesterol levels, inhibited inflammation, and protected intestinal barrier function.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042101","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T21:00:59Z","timestamp":1744664459000},"page":"e42101","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of sodium butyrate in improving nonalcoholic fatty liver disease: A meta-analysis of preclinical studies"],"prefix":"10.1097","volume":"104","author":[{"given":"Hongxin","family":"Xu","sequence":"first","affiliation":[{"name":"Department of General Medicine, Ninth People\u2019s Hospital of Zhengzhou, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[{"name":"Second Clinical Medical College, Binzhou Medical University, Yantai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoujun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-6355","authenticated-orcid":false,"given":"Lingyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250414","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines.","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J Hepatol"},{"key":"R2-20250414","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"R3-20250414","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"R4-20250414","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"R5-20250414","first-page":"284","article-title":"Lipotoxicity in HepG2 cells triggered by free fatty acids.","volume":"3","author":"Yao","year":"2011","journal-title":"Am J Transl Res"},{"key":"R6-20250414","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"R7-20250414","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review.","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"R8-20250414","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/1751-2980.12709","article-title":"Role of gut microbial metabolites in nonalcoholic fatty liver disease.","volume":"20","author":"Zhao","year":"2019","journal-title":"J Dig Dis"},{"key":"R9-20250414","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3748\/wjg.v17.i12.1519","article-title":"Potential beneficial effects of butyrate in intestinal and extraintestinal diseases.","volume":"17","author":"Canani","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R10-20250414","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10565-020-09518-4","article-title":"Sodium butyrate modulates gut microbiota and immune response in colorectal cancer liver metastatic mice.","volume":"36","author":"Ma","year":"2020","journal-title":"Cell Biol Toxicol"},{"key":"R11-20250414","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/JOE-19-0122","article-title":"Effect of exercise and butyrate supplementation on microbiota composition and lipid metabolism.","volume":"243","author":"Yu","year":"2019","journal-title":"J Endocrinol"},{"key":"R12-20250414","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/JOE-16-0322","article-title":"Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC.","volume":"232","author":"Dong","year":"2017","journal-title":"J Endocrinol"},{"key":"R13-20250414","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1530\/JOE-18-0137","article-title":"Sodium butyrate supplementation ameliorates diabetic inflammation in db\/db mice.","volume":"238","author":"Xu","year":"2018","journal-title":"J Endocrinol"},{"key":"R14-20250414","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3390\/nu12040951","article-title":"Oral supplementation of sodium butyrate attenuates the progression of non-alcoholic steatohepatitis.","volume":"12","author":"Baumann","year":"2020","journal-title":"Nutrients"},{"key":"R15-20250414","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"R16-20250414","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110994","article-title":"Sodium butyrate arrests pancreato-hepatic synchronous uric acid and lipid dysmetabolism in high fat diet fed Wistar.","volume":"133","author":"Adeyanju","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R17-20250414","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1017\/S0007114515003621","article-title":"Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH).","volume":"114","author":"Jin","year":"2015","journal-title":"Br J Nutr"},{"key":"R18-20250414","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1017\/S0007114516004025","article-title":"Sodium butyrate protects mice from the development of the early signs of non-alcoholic fatty liver disease: role of melatonin and lipid peroxidation.","volume":"116","author":"Jin","year":"2016","journal-title":"Br J Nutr"},{"key":"R19-20250414","doi-asserted-by":"crossref","first-page":"e68626","DOI":"10.1371\/journal.pone.0068626","article-title":"Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet.","volume":"8","author":"Mattace Raso","year":"2013","journal-title":"PLoS One"},{"key":"R20-20250414","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1021\/acs.jafc.8b01189","article-title":"Sodium butyrate ameliorates high-fat-diet-induced non-alcoholic fatty liver disease through peroxisome proliferator-activated receptor alpha-mediated activation of beta oxidation and suppression of inflammation.","volume":"66","author":"Sun","year":"2018","journal-title":"J Agric Food Chem"},{"key":"R21-20250414","doi-asserted-by":"crossref","first-page":"10675","DOI":"10.1039\/D0FO01954B","article-title":"Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db\/db mice.","volume":"11","author":"Yang","year":"2020","journal-title":"Food Funct"},{"key":"R22-20250414","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3389\/fmicb.2018.01967","article-title":"Butyrate protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by improving gut barrier function, attenuating inflammation and reducing endotoxin levels.","volume":"9","author":"Ye","year":"2018","journal-title":"Front Microbiol"},{"key":"R23-20250414","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/1440-1681.13497","article-title":"Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression.","volume":"48","author":"Zhang","year":"2021","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R24-20250414","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcmgh.2021.05.006","article-title":"Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene.","volume":"12","author":"Zhao","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"R25-20250414","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3748\/wjg.v23.i1.60","article-title":"Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.","volume":"23","author":"Zhou","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R26-20250414","first-page":"1664","article-title":"Sodium butyrate in combination with berberine improves nonalcoholic fatty liver disease in C57BL\/6J mice.","volume":"35","author":"Zhang","year":"2019","journal-title":"Chin Pharmacological Bulletin"},{"key":"R27-20250414","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.27395","article-title":"The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.","volume":"61","author":"Maximos","year":"2015","journal-title":"Hepatology"},{"key":"R28-20250414","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.3390\/ijms20081948","article-title":"Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview.","volume":"20","author":"Marchisello","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R29-20250414","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0183-1","article-title":"Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.","volume":"50","author":"Zhou","year":"2018","journal-title":"Exp Mol Med"},{"key":"R30-20250414","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3390\/ijms12053117","article-title":"Inflammation, oxidative stress, and obesity.","volume":"12","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2011","journal-title":"Int J Mol Sci"},{"key":"R31-20250414","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1111\/liv.12523","article-title":"Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?","volume":"34","author":"Tariq","year":"2014","journal-title":"Liver Int"},{"key":"R32-20250414","doi-asserted-by":"crossref","first-page":"e0145940","DOI":"10.1371\/journal.pone.0145940","article-title":"Mechanism of butyrate stimulation of triglyceride storage and adipokine expression during adipogenic differentiation of porcine stromovascular cells.","volume":"10","author":"Yan","year":"2015","journal-title":"PLoS One"},{"key":"R33-20250414","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/gutjnl-2017-314050","article-title":"Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit.","volume":"67","author":"Li","year":"2018","journal-title":"Gut"},{"key":"R34-20250414","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The claude bernard lecture 2009.","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"R35-20250414","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1478-3231.2006.01342.x","article-title":"Role of Kupffer cells in host defense and liver disease.","volume":"26","author":"Bilzer","year":"2006","journal-title":"Liver Int"},{"key":"R36-20250414","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s10753-017-0628-z","article-title":"NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in Kupffer cells induced by palmitic acid.","volume":"40","author":"Cai","year":"2017","journal-title":"Inflammation"},{"key":"R37-20250414","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1179\/096805100101532414","article-title":"Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysaccharide through Toll-like receptors.","volume":"6","author":"Zhang","year":"2000","journal-title":"J Endotoxin Res"},{"key":"R38-20250414","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1499-3872(15)60026-1","article-title":"Gut microbiota and non-alcoholic fatty liver disease.","volume":"14","author":"Gkolfakis","year":"2015","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R39-20250414","first-page":"28","article-title":"The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome.","volume":"17","author":"Lewandowski","year":"2022","journal-title":"Prz Gastroenterol"},{"key":"R40-20250414","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.3748\/wjg.v19.i33.5402","article-title":"What does irritable bowel syndrome share with non-alcoholic fatty liver disease?","volume":"19","author":"Scalera","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R41-20250414","doi-asserted-by":"crossref","first-page":"e63388","DOI":"10.1371\/journal.pone.0063388","article-title":"Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.","volume":"8","author":"Endo","year":"2013","journal-title":"PLoS One"},{"key":"R42-20250414","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s10620-012-2259-4","article-title":"Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription.","volume":"57","author":"Wang","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"Suppl 4","key":"R43-20250414","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2527\/jas.50965","article-title":"Butyrate promotes the recovering of intestinal wound healing through its positive effect on the tight junctions.","volume":"90","author":"Ma","year":"2012","journal-title":"J Anim Sci"},{"key":"R44-20250414","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1203\/01.pdr.0000250014.92242.f3","article-title":"Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier.","volume":"61","author":"Peng","year":"2007","journal-title":"Pediatr Res"},{"key":"R45-20250414","doi-asserted-by":"crossref","first-page":"e0179586","DOI":"10.1371\/journal.pone.0179586","article-title":"Butyrate modifies intestinal barrier function in IPEC-J2 cells through a selective upregulation of tight junction proteins and activation of the Akt signaling pathway.","volume":"12","author":"Yan","year":"2017","journal-title":"PLoS One"},{"key":"R46-20250414","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1749-6632.2012.06553.x","article-title":"Microbial butyrate and its role for barrier function in the gastrointestinal tract.","volume":"1258","author":"Pl\u00f6ger","year":"2012","journal-title":"Ann N Y Acad Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T21:01:06Z","timestamp":1744664466000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":46,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042101","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}